News · 26 weeks57-62%
2026-02-012026-07-26
Mix3090d
- SEC Filings12(40%)
- Insider12(40%)
- Analyst3(10%)
- Other3(10%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Evommune Inc.SCHEDULE 13G - Evommune, Inc. (0002044725) (Subject)
- INSIDERChief Financial Officer Carver Kyle bought $13,260 worth of shares (1,000 units at $13.26), increasing direct ownership by 2% to 60,335 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERDirector Kirsch Arthur S bought $133,000 worth of shares (10,000 units at $13.30) (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- ANALYSTEvommune downgraded by H.C. WainwrightH.C. Wainwright downgraded Evommune from Buy to Neutral
- ANALYSTEvommune downgraded by William BlairWilliam Blair downgraded Evommune from Outperform to Mkt Perform
- SECSEC Form 424B3 filed by Evommune Inc.424B3 - Evommune, Inc. (0002044725) (Filer)
- SECEvommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
- PREvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria- Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks- Evommune to continue development of EVO756 in Atopic Dermatitis and MigraineEvommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (CSU).The Phase 2b trial enrolled 160 moderate-to-severe antihist
- INSIDERChief of Dev. Operations Drew Janice Suzann exercised 20,000 shares at a strike of $3.15 and sold $452,600 worth of shares (20,000 units at $22.63) as part of a pre-agreed trading plan (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERChief Scientific Officer Patel Jeegar Pravinkumar exercised 1,488 shares at a strike of $3.84 and sold $33,480 worth of shares (1,488 units at $22.50) as part of a pre-agreed trading plan (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERPresident & CEO Pena Luis C. sold $168,917 worth of shares (7,438 units at $22.71) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 630,458 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcgraw Benjamin F Iii4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERSEC Form 4 filed by Director Kirsch Arthur S4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERDirector Cohen David E sold $123,094 worth of shares (6,056 units at $20.33) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 17,609 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERChief Scientific Officer Patel Jeegar Pravinkumar sold $379,462 worth of shares (16,687 units at $22.74) as part of a pre-agreed trading plan and exercised 13,512 shares at a strike of $3.84, decreasing direct ownership by 6% to 46,403 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERPresident & CEO Pena Luis C. sold $381,736 worth of shares (16,787 units at $22.74) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 637,896 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- SECSEC Form 144 filed by Evommune Inc.144 - Evommune, Inc. (0002044725) (Subject)
- SECSEC Form 424B3 filed by Evommune Inc.424B3 - Evommune, Inc. (0002044725) (Filer)
- SECEvommune Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Evommune, Inc. (0002044725) (Filer)
- INSIDERChief Business & Legal Officer Moss Gregory S. exercised 14,223 shares at a strike of $1.71 and sold $324,711 worth of shares (14,223 units at $22.83) as part of a pre-agreed trading plan (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERChief Financial Officer Carver Kyle exercised 15,000 shares at a strike of $2.99 and sold $415,117 worth of shares (18,175 units at $22.84) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 59,335 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- SECSEC Form 144 filed by Evommune Inc.144 - Evommune, Inc. (0002044725) (Subject)
- SECSEC Form 144 filed by Evommune Inc.144 - Evommune, Inc. (0002044725) (Subject)
- SECSEC Form 144 filed by Evommune Inc.144 - Evommune, Inc. (0002044725) (Subject)
- SECSEC Form 424B3 filed by Evommune Inc.424B3 - Evommune, Inc. (0002044725) (Filer)
EVMN FAQ
6 questionsWhere does EVMN stock trade?
Evommune Inc. (EVMN) is listed on NYSE.What sector and industry is EVMN in?
Evommune Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Evommune Inc. go public?
Evommune Inc. (EVMN) completed its IPO in 2025.What are analysts saying about EVMN?
Evommune Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-06-30. Recent price targets range from $3500.00 to $4200.00.What companies are similar to EVMN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EVMN side-by-side with any of them on Quantisnow.How can I track EVMN on Quantisnow?
Quantisnow aggregates Evommune Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EVMN to receive live email and push alerts on every new disclosure.